AI-Powered Aptamer Optimization for More Predictable Discovery
We help biotech teams prioritize only high-quality aptamer candidates before synthesis and wet-lab validation – cutting timelines, costs, and experimental risks.
Fewer Failures. Better Candidates. Faster Discovery.
Learn moreLower Total Cost of Aptamer Development
By removing low-potential sequences early, teams typically reduce the cost of early discovery by 30–50%.
Shorter, More Predictable Discovery Cycles
Aptamer teams typically waste up to 60–80% of early discovery time cycling through unstable or low-value sequences.
De-Risking SELEX and Enrichment Workflows
Our optimization approach reduces these risks by prioritizing sequences with the highest probability of meaningful enrichment – so wet-lab teams start each round with a far stronger pool.
Delivering Higher-Quality Aptamer Candidates
Higher-quality profiles translate directly into higher hit rates during SELEX refinement and downstream development.
Reducing Wet-Lab Attrition Rates
We help teams avoid these failures by identifying weak or non-viable candidates before they reach the bench.
Biotech
Industry
USA
Location
Drug Discovery, AI compound screening, Chemical space optimization
Services
$200,000 to $999,999
Budget
The team showed initiative and proactiveness in developing alternative solutions to reach our goals. As a result, we obtained very complex and high-quality support.
Under NDA
CEO, Chemistry Solutions CompanyWho This Is For
Aptamer Discovery & SELEX Providers
-
Companies that run systematic SELEX campaigns and need to reduce enrichment failures, improve hit quality, and accelerate project delivery for their clients.
Biotech Teams Developing Aptamer-Based Therapeutics
-
Teams advancing aptamers as drug candidates, where improved affinity, stability, and specificity directly translate into lower attrition rates and stronger downstream validation.
Diagnostics & Assay Development Companies
-
Organizations building aptamer-based diagnostics, biosensors, or analytical assays that rely on reproducible folding, high-selectivity binders, and fast iteration cycles.
Lowering manufacturing and formulation risks
-
Detecting early signs of aggregation, degradation pathways, or structural instability
Didn’t find exactly what you were looking for?
Tell us what you’re building – we’ll map out the options, evaluate feasibility, and recommend the optimal technical pathway.
Get a consultationThese case studies illustrate how our AI-driven workflows help R&D organizations improve predictability, eliminate low-value candidates, and deliver better results with fewer experiments.
Let’s build your AI advantage
Whether you’re prototyping a molecule scoring system or looking to automate your clinical ops – we’ll help you turn your biotech data into competitive edge.
Book a Meeting